Throat Cancer Monitoring With Blood Work (Signatera) in West Palm Beach, FL

Name: Throat Cancer Monitoring With Blood Work (Signatera)
Brand: AQ Surgery
Rating: 5 (12 reviews)

One of the most innovative tools in monitoring throat cancer is liquid biopsy technology, specifically the Signatera test, which uses blood work to detect and monitor cancer activity.

couple cutting carrots and cooking together

Precision Monitoring for Throat Cancer

Throat cancer, which encompasses cancers of the pharynx, larynx, and surrounding tissues, can be a life-altering diagnosis. Early detection, precise treatment, and continuous monitoring are critical for improving outcomes. Dr. Anastasiya Quimby’s expertise in head and neck oncology, combined with the cutting-edge capabilities of Signatera, offers throat cancer patients a more accurate and non-invasive method of tracking their condition, ensuring that real-time, personalized data informs treatment decisions.

What Is Signatera?

Signatera is a liquid biopsy test that monitors cancer by analyzing tumor-specific DNA fragments (ctDNA) circulating in the patient’s bloodstream. The Signatera test is highly sensitive and designed to detect small amounts of ctDNA in the blood. Traditional monitoring methods, such as imaging and tissue biopsies, often detect cancer at more advanced stages, while blood work with Signatera can identify recurrence or residual cancer much earlier. This personalized blood test is tailored to each patient, making it one of the most advanced tools available for throat cancer monitoring in West Palm Beach.

What to Expect During the Process

Throat cancer monitoring starts with analyzing the genetic profile of the patient’s tumor. After throat cancer surgery or biopsy, a sample of the tumor is sent to the laboratory, where its DNA is sequenced. This helps create a custom test that looks for specific mutations unique to that patient’s cancer. After creating the personalized tumor DNA profile, blood samples are collected from the patient at regular intervals.

These blood samples are analyzed to detect the presence of ctDNA that matches the unique genetic mutations identified in the tumor sample. The test looks for traces of ctDNA in the bloodstream. If ctDNA is detected, it may indicate that cancer cells are still present in the body, either as residual disease after treatment or as early signs of recurrence.

If no ctDNA is detected, it suggests no detectable cancer activity at that time. Signatera enables continuous, non-invasive monitoring. By comparing ctDNA levels over time, Dr. Quimby can assess the effectiveness of treatment and determine whether any changes in therapy are needed. The test can also monitor patients after treatment, catching any signs of recurrence before they become visible through imaging.

Benefits of Throat Cancer Monitoring in West Palm Beach

Early Detection of Recurrence

One of the most significant advantages of Signatera is its ability to detect cancer recurrence before it becomes visible on imaging scans or causes noticeable symptoms. For throat cancer patients, this early detection allows for timely intervention, potentially improving survival rates and reducing the severity of the disease.

Personalized Monitoring

Traditional monitoring methods rely on generalized tests and imaging, which can sometimes miss small recurrences or residual disease. Signatera is uniquely personalized to the patient’s cancer, ensuring that monitoring is specific to the mutations that caused the initial tumor. This approach increases the accuracy of detecting cancer at its earliest stages.

Non-Invasive and Convenient

Unlike traditional biopsies, which require tissue samples and invasive procedures, Signatera is a simple blood test. This makes it much more comfortable and convenient for patients, especially those requiring long-term monitoring. Patients can have regular blood tests without surgery or radiation exposure.

Real-Time Treatment Adjustments

The ability to track ctDNA levels in real time means doctors can adjust treatment plans as needed. If a patient’s ctDNA levels begin to rise, it may indicate that the cancer is not responding to treatment or that a recurrence is likely. This allows Dr. Quimby to make informed decisions about changing therapies or recommending additional treatments to prevent cancer progression.

Improved Quality of Life

Because Signatera offers a non-invasive and precise way to monitor throat cancer, patients can avoid unnecessary treatments or procedures. By providing a clearer picture of the patient’s cancer status, this test helps to reduce anxiety and uncertainty, enabling patients to focus on their recovery and well-being.

Who Is a Candidate for Signatera?

Patients with throat cancer who are undergoing treatment or who have completed treatment are ideal candidates for Signatera. It is especially beneficial for the following patients:

Patients who have completed surgery, chemotherapy, or radiation therapy and require ongoing monitoring to detect any signs of recurrence
Those who are in remission and want to track their cancer status to ensure early intervention in case of relapse
Individuals who have a high risk of recurrence based on their cancer type, stage, or treatment history

Why Choose AQ Surgery?

AQ Surgery combines Dr. Anastasiya Quimby’s head and neck oncology expertise with the most advanced diagnostic tools available, including Signatera, to provide comprehensive and personalized care. Dr. Quimby’s multidisciplinary approach ensures that each patient’s cancer is treated with the highest level of precision, and her focus on innovative monitoring techniques means that patients can enjoy peace of mind knowing their cancer is being closely watched.

Throat cancer can be challenging to manage, but with Signatera and the expert care offered by Dr. Quimby, patients can have confidence in their treatment plan and look forward to better outcomes. Whether you are in the midst of treatment or in remission, continuous monitoring with blood work ensures that you are always ahead of the curve in managing your health.

Experience Innovative Throat Cancer Care at AQ Surgery

Throat cancer monitoring with Signatera offers a groundbreaking approach to keeping track of cancer recurrence and treatment effectiveness. By using blood work to analyze ctDNA, this test provides a personalized, non-invasive, and highly accurate way to monitor throat cancer. AQ Surgery uses this advanced technology to ensure our patients receive the best care possible. If you or a loved one is managing throat cancer, contact AQ Surgery today to learn more about throat cancer monitoring in West Palm Beach as part of your cancer care plan.